ISRCTN64726310 https://doi.org/10.1186/ISRCTN64726310

Development and evaluation of Nurse Practitioner follow-up in the management of patients with lung cancer.

Submission date 23/01/2004	**Recruitment status** No longer recruiting	[_] Prospectively registered [_] Protocol [_] Statistical analysis plan [X] Results [_] Individual participant data
Registration date 23/01/2004	**Overall study status** Completed	
Last Edited 22/05/2012	**Condition category** Cancer	

Plain English summary of protocol
Not provided at time of registration

Contact information

Type(s)
Scientific

Contact name
Prof Jessica Corner

Contact details
The Institute of Cancer Research
The Centre for Cancer and Palliative Care Studies
Royal Cancer Hospital
Fulham Road
London
United Kingdom
SW3 6JJ
+44 (0)20 7352 8171

Additional identifiers

Protocol serial number
NCP/J17/18

Study information

Scientific Title

Study objectives
Not provided at time of registration

Ethics approval required
Old ethics approval format

Ethics approval(s)
Not provided at time of registration

Study design
Randomised controlled trial

Primary study design
Interventional

Study type(s)
Treatment

Health condition(s) or problem(s) studied
Cancer (neoplasms): Lung (non-small cell)

Interventions
1. Conventional medical follow-up:
At the specialist cancer hospital, patients were seen within one month and, if stable, discharged back to their referring cancer unit. At the cancer units, follow-up was 2 - 3 monthly if patients were stable. At all centres, patients who were not considered medically stable were seen on the basis of need.
2. Nurse-led follow-up:
Patients allocated to one of two Clinical Nurse Specialists (CNS) who took responsibility for their follow-up care for one year. Patients assessed monthly or on basis of need by telephone or at a nurse-led clinic. Patients could also use a paging system to contact CNS if they had concerns during intervals between assessments. Focus of care was not only disease surveillance but also the physical, psychological and social needs of patients and their families. Emphasis on prompt communication and liaison with primary care teams. Patients attended hospital medical clinics only if their condition indicated this was needed or if patients requested a consultation with a hospital physician.

Intervention Type
Other

Phase
Not Specified

Primary outcome(s)
Not provided at time of registration

Key secondary outcome(s))
Not provided at time of registration

Completion date
01/01/2001

Eligibility

Key inclusion criteria
1. Patients with lung cancer having completed initial treatment
2. Not requiring immediate medical intervention or close medical supervision
3. Considered to have a good performance status (World Health Organization [WHO] performance status 0 - 2)
4. Had an expected prognosis of at least 3 months
5. Were not participating in other clinical trials requiring intensive medical investigation or follow-up
6. Understood and read English for informed consent and data collection purposes

Participant type(s)
Patient

Healthy volunteers allowed
No

Age group
Not Specified

Sex
Not Specified

Key exclusion criteria
Not provided at time of registration

Date of first enrolment
01/01/1999

Date of final enrolment
01/01/2001

Locations

Countries of recruitment
United Kingdom

England

Study participating centre
The Institute of Cancer Research
London
United Kingdom
SW3 6JJ

Sponsor information

Organisation
Record Provided by the NHS R&D 'Time-Limited' National Programme Register - Department of Health (UK)

Funder(s)

Funder type
Government

Funder Name
NHS Cancer National Research and Development Programme (UK)

Results and Publications

Individual participant data (IPD) sharing plan

IPD sharing plan summary
Not provided at time of registration

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article	Results	16/11/2002		Yes	No
Participant information sheet	Participant information sheet	11/11/2025	11/11/2025	No	Yes